Todd Tushla | VP, IR |
Kevin Gorman | CEO |
Matt Abernethy | CFO |
Eric Benevich | Chief Commercial Officer |
Eiry Roberts | Chief Medical Officer |
Kyle Gano | Chief Business Development & Strategy Officer |
Philip Nadeau | Cowen & Company |
Tazeen Ahmad | Bank of America |
Paul Matteis | Stifel |
Josh Schimmer | Evercore |
Neena Bitritto-Garg | Citi |
Chris Shibutani | Goldman Sachs |
Brian Abrahams | RBC Capital Markets |
Anupam Rama | JPMorgan |
Carter Gould | Barclays |
Myles Minter | William Blair |
Marc Goodman | SVB Securities |
Brian Skorney | Baird |
Danielle Brill | Raymond James |
Jay Olson | Oppenheimer |
Laura Chico | Wedbush Securities |
Sumant Kulkarni | Canaccord Genuity |
David Amsellem | Piper Sandler |
Akash Tewari | Jefferies |
Ashwani Verma | UBS |
Yatin Suneja | Guggenheim Partners |
Uy Ear | Mizuho Securities |
Ami Fadia | Needham |
Good day, everyone, and welcome to the Neurocrine Biosciences Reports First Quarter Results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Please note this call may be recorded and I will be standing by should you need any assistance.
It is now my pleasure to turn the call over to Todd Tushla, Vice President of Investor Relations.